Obesity Action Coalition publishes its first assessment of the Bridge's opening weeks

The Obesity Action Coalition (OAC), a patient advocacy group that has pushed for years for Medicare to cover obesity treatment, has published its first assessment of the Medicare GLP-1 Bridge, a temporary program that opened July 1, 2026 ^[1]. The group called the launch "an important policy step" but stressed it does not solve every access problem or provide comprehensive obesity care ^[1].

The Bridge is a demonstration run by the Centers for Medicare & Medicaid Services (CMS) that lets eligible Medicare Part D beneficiaries get certain GLP-1 medications for chronic weight management at a $50 monthly copay ^[1]. It is scheduled to run through December 31, 2027 ^[1]. Unlike standard Part D coverage, the Bridge uses a separate nationwide process for prior authorization, pharmacy claims, and payment, which means beneficiaries, doctors, and pharmacies are all adjusting to a new system at once ^[1].

OAC said it is too early to draw broad conclusions about whether the program is succeeding. Instead, the group says it is tracking what is working, where barriers are showing up, and what could be improved, arguing that coverage "only fulfills its promise when people can actually access appropriate care" ^[1]. The group has also set up a Medicare Bridge Resource Hub to help beneficiaries with eligibility questions, prior authorization, and pharmacy issues ^[1].

OAC pointed to a broader reason the early weeks matter: CMS has said it will use utilization data from the Bridge to help shape future Medicare policy on GLP-1 coverage ^[1]. That means how smoothly people move through the program now could influence whether and how Medicare expands obesity drug coverage after the demonstration ends. Separately, OAC reported that the Treat and Reduce Obesity Act, a longstanding bill that would expand Medicare coverage of obesity treatments, has reached 51 cosponsors in the House and 19 in the Senate ^[2].

Why it matters for patients

For Medicare beneficiaries who have struggled to get GLP-1 medications covered, the Bridge offers a concrete, if temporary, path to a $50 monthly copay ^[1]. But OAC's own framing makes clear this is not a permanent fix: the program has an end date of December 31, 2027, and it does not guarantee comprehensive obesity care for everyone who might benefit ^[1].

Because the Bridge relies on a new, separate administrative process for prior authorization and claims, patients and their doctors may encounter unfamiliar paperwork or delays while the system is worked out ^[1]. OAC's advice to patients experiencing problems is to use resources like its Bridge hub to understand eligibility and pharmacy steps, though the sources do not detail specific complaints or failure rates from the first two months ^[1].

The stakes extend beyond current enrollees. Because CMS says it will use Bridge data to inform future Medicare policy, how the program performs now could affect whether wider, more permanent GLP-1 coverage becomes available to Medicare beneficiaries later ^[1]. Meanwhile, the slow but steady growth in cosponsors for the Treat and Reduce Obesity Act—now at 51 in the House and 19 in the Senate—signals continued, if incremental, congressional interest in a legislative fix that would not depend on a temporary demonstration ^[2].

What happens next

The Bridge is set to continue through December 31, 2027 ^[1]. OAC says it will keep monitoring the program, gathering input from patients, and pressing CMS to address barriers as they emerge, while continuing to advocate for broader, more permanent obesity-care coverage ^[1]. The sources do not specify a timeline for CMS to release Bridge utilization data or for further congressional action on the Treat and Reduce Obesity Act.